Výsledky vyhledávání - "Charles Mylander"

Akademický článek

Complications after Oncoplastic Breast Reduction and Impact on Time to Adjuvant Therapy

Autor: Micaela Moen, MD, Tripp Holton, MD, Angelina Phung, Shivani Badve, MD, Charles Mylander, PhD, Thomas Sanders, PhD, Margaret Pauliukonis, MD, Rubie Sue Jackson, MD, MPH

Publikováno v: Plastic and Reconstructive Surgery, Global Open, Vol 12, Iss 7, p e6010 (2024)

Background:. Although lumpectomy with oncoplastic breast reduction (OBR) improves cosmetic results and ameliorates symptomatic macromastia, associated complications may delay adjuvant therapy. Methods:. This was a single-institution, retrospective st

Externí odkaz: https://doaj.org/article/24ea279f9f11485680bdb4741c45b201

Zobrazit plný text záznamu

Akademický článek

Outcomes of Margin Reexcision after Oncoplastic Breast Reduction

Autor: Tasha A. Martin, MD, Salman Choudhry, MD, Luther H. Holton, MD, W. Charles Mylander, PhD, Lorraine Tafra, MD, Wen Liang, DO, Rubie Sue Jackson, MD, MPH

Publikováno v: Plastic and Reconstructive Surgery, Global Open, Vol 10, Iss 9, p e4509 (2022)

Introduction:. Tissue rearrangement after an oncoplastic breast reduction may complicate identification of margins during reexcision. Little is known about outcomes of reoperation in this setting. Methods:. This is a single-institution, retrospective

Externí odkaz: https://doaj.org/article/182bde8d14a04350abe00bf4ae55f096

Zobrazit plný text záznamu

The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?

Autor: Carol Tweed, Nicholas Huerta, Lorraine Tafra, Rubie Sue Jackson, Charles Mylander, Martin Rosman, Laura Martino, Kip Waite, Elaine Lee

Publikováno v: Clinical Breast Cancer. 21:e731-e737

Introduction With the advent of genomic assays, sentinel lymph node biopsy (SLNB) may be less impactful in determining adjuvant breast cancer therapy. We evaluated the influence of SLNB on adjuvant therapy recommendation when the Oncotype DX recurren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51cfa1f213472e645a82a37a59fb0598
https://doi.org/10.1016/j.clbc.2021.02.011

Zobrazit plný text záznamu

Abstract P4-06-01: OncotypeDX testing does not appear to benefit patients with grade 1, progesterone receptor positive breast cancers: A TAILORx validated study

Autor: Young Lee, W. Charles Mylander, Tasha Martin, Martin Rosman, Thomas J Sanders, Udai S Sibia, Lorraine Tafra, Rubie S Jackson

Publikováno v: Cancer Research. 82:P4-06

Background: We previously described a validated (AAMC) risk prediction model, based on pathology, which may eliminate the need for OncotypeDX testing in AAMC low-risk (grade 1, progesterone (PR) positive) tumors. Our previous study used the SEER data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0b65b187214880b9d809bd927efff58
https://doi.org/10.1158/1538-7445.sabcs21-p4-06-01

Zobrazit plný text záznamu

Abstract P1-10-02: Recurrence score testing does not appear to benefit patients with grade I PR positive breast cancers: An opportunity to eliminate over-treatment and decrease testing costs

Autor: Martin Rosman, Lorraine Tafra, Charles Mylander, Thomas Sanders, Rubie Sue Jackson

Publikováno v: Cancer Research. 80:P1-10

Background: We previously showed that a risk prediction model (AAMC model) based on standard pathology data can eliminate the need for Recurrence Score (RS) testing in a large proportion of cases. There is concern about whether cases with discordant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e75511a1aee3bb953f22f1c0cd62635
https://doi.org/10.1158/1538-7445.sabcs19-p1-10-02

Zobrazit plný text záznamu

Ultrasound-Based Nomogram Identifies Breast Cancer Patients Unlikely to Harbor Axillary Metastasis: Towards Selective Omission of Sentinel Lymph Node Biopsy

Autor: Martin Rosman, Daina Pack, Hanh Tam Tran, Laura Martino, Rubie Sue Jackson, Lorraine Tafra, Charles Mylander

Publikováno v: Annals of Surgical Oncology. 27:2679-2686

As tumor biology takes precedence over anatomic staging to determine breast cancer (BC) prognosis, there is growing interest in limiting axillary surgery. There is a need for tools to identify patients at the lowest risk of harboring axillary lymph n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::907b1eff595e7e41806cdba76d216d70
https://doi.org/10.1245/s10434-019-08164-3

Zobrazit plný text záznamu

Post-operative stereotactic radiosurgery of brain metastases: A single-center retrospective review of clinical outcomes

Autor: Zachary T. Smith, Kerry J. Thompson, Brian Hasson, Luqman K. Dad, Syed U. Ashruf, Charles Geraghty, Timothy G. Burke, Charles Mylander

Publikováno v: Journal of Radiotherapy in Practice. 19:127-131

Aim:We sought to retrospectively report our outcomes using post-operative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in place of whole-brain radiation therapy (WBRT) following resection of brain metastases from our hospital-based

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9739be53f9cbbb005107b5bdd52a155e
https://doi.org/10.1017/s1460396919000268

Zobrazit plný text záznamu

Recurrence Score Testing Does not Appear to Benefit Patients With Grade 1, Progesterone Receptor-Positive Breast Cancers: An Opportunity to Eliminate Overtreatment and Decrease Testing Costs

Autor: Charles Mylander, Udai S. Sibia, Carol Tweed, Thomas Sanders, Rubie Sue Jackson, Martin Rosman, Lorraine Tafra

Publikováno v: Hematology/oncology and stem cell therapy. 15(1)

Background We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f37c4d3885b6eaac2234f9dd5f3db738
https://pubmed.ncbi.nlm.nih.gov/34174200

Zobrazit plný text záznamu

Abstract P3-09-05: Getting the most out of the 21-gene recurrence score assay: Increasing actionable results with a combined pathologic-genomic model

Autor: Anjali James, Charles Mylander, JR Espinosa Fernandez, Lorraine Tafra, Rubie Sue Jackson, Arup Kumar Sinha, Martin Rosman, Michele M. Gage, Takeo Fujii, Akshara Singareeka Raghavendra, F Le Du, NT Ueno

Publikováno v: Cancer Research. 78:P3-09

Introduction: The 21-gene recurrence score (RS) assay categorizes hormone receptor positive, node negative breast cancers (BC) into 3 risk groups for recurrence. We previously showed that the AAMC Model, using only standard pathology data, accurately

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0f2f972bbc3061f8cc060f8b1a1f855
https://doi.org/10.1158/1538-7445.sabcs17-p3-09-05

Zobrazit plný text záznamu

Abstract P2-05-13: Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors

Autor: ME Pozo, Antonio C. Wolff, Christopher B. Umbricht, Martin Rosman, M Winner, Lorraine Tafra, Charles Mylander, Rubie Sue Jackson

Publikováno v: Cancer Research. 77:P2-05

Background/objective: A minority of estrogen-receptor (ER) positive breast cancers lack progesterone receptor (PR) expression, but little is known of the clinical meaning of PR negativity (PR-). In the present study we sought to clarify the associati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54546b3a11fcd1a6b97903859f3c317c
https://doi.org/10.1158/1538-7445.sabcs16-p2-05-13

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání